FE 999049

DRUG4 trials

Sponsors

Ferring Pharmaceuticals

Conditions

InfertilityInfertility, FemaleMale Idiopathic Infertility

Phase 2

A Dose-response Trial Using rFSH FE 999049 in Women Undergoing IVF/ICSI Treatment

CompletedNCT01426386

Ferring PharmaceuticalsInfertility

Start: 2011-09-30End: 2013-03-31Updated: 2020-11-17

A Dose-response Trial Using FE 999049 in Japanese Women Undergoing in Vitro Fertilisation (IVF) / Intracytoplasmic Sperm Injection (ICSI) Treatment

CompletedNCT02309671

Ferring PharmaceuticalsInfertility

Start: 2014-12-31End: 2016-09-30Updated: 2020-12-14

A Trial to Compare Efficacy and Safety of Follitropin Delta Versus Placebo (Inactive Treatment) in the Treatment of Men With Idiopathic Infertility (Unexplained Reduction of Semen Quality) (ADAM)

TerminatedNCT05403476

Ferring PharmaceuticalsMale Idiopathic Infertility

Start: 2022-08-16End: 2024-10-23Updated: 2024-11-21

Phase 3

A Randomised Trial Comparing the Ovarian Response of a Starting Dose of Either 10 μg or 15 μg Follitropin Delta (FE 999049) to a Starting Dose of Either 150 IU or 225 IU Follitropin Alfa (GONAL-F) in Conventional Regimens in China

CompletedNCT06173869

Ferring PharmaceuticalsInfertility, Female

Start: 2024-03-29End: 2025-05-31Updated: 2026-02-12

Related Papers

O-013 Population pharmacokinetics of follitropin delta during ovarian stimulation

Human Reproduction2024-07-01

P-671 Modelling human follicle growth and development during ovarian stimulation: a physiological computational approach

Human Reproduction2024-07-01

P–650 Body weight is the main determinant of systemic follicle stimulating hormone (FSH) concentrations during controlled ovarian stimulation with follitropin delta

Human Reproduction2021-07-013 citations

Randomized, assessor-blind, antimüllerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta

Fertility and Sterility2020-12-0423 citations

Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimüllerian hormone–stratified, dose–response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection

Fertility and Sterility2014-09-23184 citations